Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101317 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
A Phase 2 study of Endometriosis, sponsored by Hope Medicine (Nanjing) Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 5
- Study locations
NCT05101317: Completed Phase 2 study of Endometriosis, sponsored by Hope Medicine (Nanjing) Co..
NCT05101317 is a Phase 2 study of Endometriosis that has completed, run by Hope Medicine (Nanjing) Co.. The registered enrollment target is 142 participants, below the 261-participant average among 48 other Endometriosis trials with a reported enrollment target (46% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05101317, a Phase 2 study of Endometriosis, has completed, sponsored by Hope Medicine (Nanjing) Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Primary Outcome
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HMI-115
Study Locations (5)
Utah
- Physicians' Research Options, LLC- Corner Canyon Clinic - Draper
Virginia
- Tidewater Clinical Research/TPW - Norfolk
Beijing Municipality
- Peking Union Medical College Hospital - Beijing
Masovian Voivodeship
- Instytut Matki i Dziecka - Warsaw
Podlaskie Voivodeship
- Specjalistyczna Poradnia Ginekologiczna Gabinet Ginekologiczny Dr med. Janusza Tomaszewskiego - Bialystok
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 2 |
What the finished NCT05101317 record still lists
NCT05101317 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 261-participant average among 48 other Endometriosis trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05101317 lists 5 locations in 5 states (Utah, Virginia, Beijing Municipality).
Frequently Asked Questions
What is clinical trial NCT05101317 about?
NCT05101317 is a clinical study titled "A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain". This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
What is the current status of trial NCT05101317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2021-10-11. Estimated completion is 2025-03-19.
What conditions does trial NCT05101317 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT05101317?
The interventions under investigation include: Placebo (DRUG), HMI-115 (DRUG).
Who is sponsoring clinical trial NCT05101317?
This trial is sponsored by Hope Medicine (Nanjing) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05101317 being conducted?
This trial has 5 study locations across Utah, Virginia, Beijing Municipality, Masovian Voivodeship, Podlaskie Voivodeship. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05101317's enrollment target sits among peer trials
142 12th of 48 higher than 37 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI